TP53 and metabolic dysfunction-associated steatotic liver disease: The inhibition of the p53/miR-34a/SIRT1 pathway prevented the miR-34a-mediated repression of SIRT1 and lead to reduced p53 acetylation and apoptosis, thus representing a novel therapeutic target for NAFLD progression.